HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VCRP Product Reporting To FDA Drops 25% In FY 2014

This article was originally published in The Rose Sheet

Executive Summary

The number of cosmetic product formulations reported to FDA through its Voluntary Cosmetic Registration Program dipped 25% from fiscal 2013 to fiscal 2014. A detailed infographic tracks participation in the program over the past six years.

You may also be interested in...

Cosmetic Adverse Event Reports Spiked 56% In Fiscal 2014 – FDA

According to FDA’s Office of Cosmetics and Colors, the number of cosmetic adverse events reported to the agency reached 491 in fiscal 2014, a 56% increase over fiscal 2013. FDA reps say the agency’s data can be deceptive and the total number likely would be higher if cosmetic adverse-event reporting were mandatory.

Fourth Time’s A Charm? President’s FY 2016 Budget Includes Cosmetic Fees

Continuing what has become a familiar refrain, the Obama administration’s fiscal 2016 budget request for FDA includes cosmetics user fees, marking the fourth consecutive year that such a system has been proposed. Legislation would need to be introduced – and passed – in order to establish cosmetics user fees.

Council-Approved Cosmetics Safety Bill Launches

Rep. Leonard Lance, R-N.J., introduces the Cosmetic Safety Amendments Act of 2012, with “the full support” of the Personal Care Products Council. Bill would not require manufacturers to substantiate product safety prior to market or pay user fees, but it does include registration, ingredient disclosure and adverse-event reporting requirements and proposes a significant increase in FDA’s oversight role.

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts